These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Elevated urokinase-type plasminogen activator level and bleeding in amyloidosis: case report and literature review. Sane DC; Pizzo SV; Greenberg CS Am J Hematol; 1989 May; 31(1):53-7. PubMed ID: 2495717 [TBL] [Abstract][Full Text] [Related]
3. Excessive fibrinolysis in AL-amyloidosis is induced by urokinae-type plasminogen activator from bone marrow plasma cells. Uchiba M; Imamura T; Hata H; Tatetsu H; Yonemura Y; Ueda M; Wada Y; Mitsuya H; Ando Y Amyloid; 2009; 16(2):89-93. PubMed ID: 20536401 [TBL] [Abstract][Full Text] [Related]
4. Fibrinolysis and coagulation in patients with infectious disease and sepsis. Philippé J; Offner F; Declerck PJ; Leroux-Roels G; Vogelaers D; Baele G; Collen D Thromb Haemost; 1991 Mar; 65(3):291-5. PubMed ID: 1904655 [TBL] [Abstract][Full Text] [Related]
5. Plasminogen activators in alcoholic cirrhosis: demonstration of increased tissue type and urokinase type activator. Booth NA; Anderson JA; Bennett B J Clin Pathol; 1984 Jul; 37(7):772-7. PubMed ID: 6235248 [TBL] [Abstract][Full Text] [Related]
6. Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus. Glas-Greenwalt P; Kant KS; Allen C; Pollak VE J Lab Clin Med; 1984 Dec; 104(6):962-76. PubMed ID: 6239000 [TBL] [Abstract][Full Text] [Related]
7. Increased plasma levels of urokinase-type plasminogen activator with endometrial and cervical cancer. Koelbl H; Kirchheimer JC; Tatra G; Christ G; Binder BR Obstet Gynecol; 1988 Aug; 72(2):252-6. PubMed ID: 3134631 [TBL] [Abstract][Full Text] [Related]
8. [Serial changes in hemostatic and fibrinolytic states induced by coronary thrombolytic therapy]. Goto S; Handa S; Abe S; Takahashi E; Kawai Y; Watanabe K; Yoshikawa T; Hori S; Ikeda Y J Cardiol; 1993; 23(4):335-41. PubMed ID: 8064582 [TBL] [Abstract][Full Text] [Related]
9. The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. Ichinose A; Fujikawa K; Suyama T J Biol Chem; 1986 Mar; 261(8):3486-9. PubMed ID: 3081506 [TBL] [Abstract][Full Text] [Related]
10. Purification of a plasminogen activator inhibitor indistinguishable from alpha1-antitrypsin and an urokinase inhibitor in pregnancy plasma. Clemmensen I; Thorsen S; Müllertz S Haemostasis; 1976; 5(4):218-30. PubMed ID: 826461 [TBL] [Abstract][Full Text] [Related]
11. Potentiation by Lys-plasminogen of clot lysis by single or two chain urokinase-type plasminogen activator or tissue-type plasminogen activator. Watahiki Y; Scully MF; Ellis V; Kakkar VV Thromb Haemost; 1989 Jun; 61(3):502-6. PubMed ID: 2508259 [TBL] [Abstract][Full Text] [Related]
12. Inactivation of single-chain urokinase-type plasminogen activator by thrombin in human subjects. Braat EA; Levi M; Bos R; Haverkate F; Lassen MR; de Maat MP; Rijken DC J Lab Clin Med; 1999 Aug; 134(2):161-7. PubMed ID: 10444030 [TBL] [Abstract][Full Text] [Related]
13. Urokinase-like plasminogen activator increased in plasma after alcohol drinking. Sumi H; Hamada H; Tsushima H; Mihara H Alcohol Alcohol; 1988; 23(1):33-43. PubMed ID: 3128990 [TBL] [Abstract][Full Text] [Related]
14. Plasminogen activators and inhibitors in normal late pregnancy, postpartum and in the postnatal period. Koh CL; Viegas OA; Yuen R; Chua SE; Ng BL; Ratnam SS Int J Gynaecol Obstet; 1992 May; 38(1):9-18. PubMed ID: 1348996 [TBL] [Abstract][Full Text] [Related]
15. The behavior of alpha2-plasmin inhibitor in fibrinolytic states. Aoki N; Moroi M; Matsuda M; Tachiya K J Clin Invest; 1977 Aug; 60(2):361-9. PubMed ID: 68962 [TBL] [Abstract][Full Text] [Related]
16. Analysis of intrinsic fibrinolysis in human plasma induced by dextran sulfate. Tsuda H; Miyata T; Iwanaga S; Yamamoto T Thromb Haemost; 1992 Apr; 67(4):440-4. PubMed ID: 1631792 [TBL] [Abstract][Full Text] [Related]
17. Inactivation of plasminogen activator inhibitor type 1 by activated factor XII plays a role in the enhancement of fibrinolysis by contact factors in-vitro. Tanaka A; Suzuki Y; Sugihara K; Kanayama N; Urano T Life Sci; 2009 Jul; 85(5-6):220-5. PubMed ID: 19500599 [TBL] [Abstract][Full Text] [Related]
18. Relationship between plasma levels of components of the fibrinolytic system and acute-phase reactants in patients with uterine malignancies. Kirchheimer JC; Kölbl H; Tatra G; Binder BR Eur J Clin Invest; 1990 Feb; 20(1):79-84. PubMed ID: 1690655 [TBL] [Abstract][Full Text] [Related]
19. Depletion of plasminogen in vitro or during thrombolytic therapy limits fibrinolytic potential. Onundarson PT; Francis CW; Marder VJ J Lab Clin Med; 1992 Jul; 120(1):120-8. PubMed ID: 1613318 [TBL] [Abstract][Full Text] [Related]
20. Isolation from human plasma of a plasminogen activator identical to urinary high molecular weight urokinase. Tissot JD; Schneider P; Hauert J; Ruegg M; Kruithof EK; Bachmann F J Clin Invest; 1982 Dec; 70(6):1320-3. PubMed ID: 6757269 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]